HEMLIBRA Financial Resources

Committed to helping you find assistance options for HEMLIBRA

Hemlibra insurance coverage icon

>95% of people nationally have insurance coverage for HEMLIBRA*

Hemlibra co-pay card icon

Eligible commercially insured patients pay as little as $5 for their medicine with the HEMLIBRA Co-pay Program. The program:

  • Helps with up to $15,000 per year in out-of-pocket (drug co-pay, co-insurance, or deductible) costs of HEMLIBRA
  • Covers up to 6 months of past HEMLIBRA treatment cost
  • Does not have any household income or other financial criteria requirements
Hemlibra access solutions icon

HEMLIBRA Access Solutions® is a program that helps people who are taking HEMLIBRA.

HEMLIBRA Access Solutions can:
Help you understand your health insurance coverage by finding out:

  • If your health insurance covers your HEMLIBRA
  • How much your co-pay will be for HEMLIBRA

Refer you to appropriate financial assistance options:

  • Genentech co-pay programs
  • Independent co-pay assistance foundations
  • Genentech Patient Foundation

There may be options that may help you afford your HEMLIBRA, no matter what type of health insurance you have. You can also get help understanding insurance coverage and financial support for HEMLIBRA by phone at (877) 233-3981.

The Genentech Patient Foundation gives free HEMLIBRA to people who don’t have insurance coverage or who have financial concerns.

Learn more about enrolling in Access Solutions.

Another resource is available

Our Hemophilia Clinical Education Managers (CEMs), a team with years of nursing/clinical experience, can provide support with insurance and financial assistance.

CEMs do not provide medical advice.

divider top

Frequently Asked Questions

Get answers to your questions about HEMLIBRA

divider bottom

*Coverage defined as a payer with a published policy for HEMLIBRA. Coverage may vary for individual and plan. Data as of July 2020.
Eligibility criteria apply. Not valid for patients using federal or state government programs to pay for their medications. Patient must be taking HEMLIBRA for an FDA-approved indication. See full terms and conditions at www.HEMLIBRACopay.com.
To be eligible for free HEMLIBRA from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including HEMLIBRA Co-pay Program and support from independent co-pay assistance foundations) and must meet certain financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet different financial criteria.

Important Safety Information & Indication


HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.

These serious side effects include: 

  • Thrombotic microangiopathy (TMA), a condition involving blood clots and injury to small blood  vessels that may cause harm to your kidneys, brain, and other organs 
  • Blood clots (thrombotic events), which may form in blood vessels in your arm, leg, lung, or head  

Talk to your doctor about the signs and symptoms of these serious side effects, which can include: 

  • Confusion
  • Stomach, chest, or back pain
  • Weakness
  • Nausea or vomiting
  • Swelling, pain, or redness
  • Feeling sick or faint
  • Decreased urination
  • Swelling of arms and legs
  • Yellowing of skin and eyes
  • Eye pain, swelling, or trouble seeing
  • Fast heart rate
  • Numbness in your face
  • Headache
  • Shortness of breath
  • Coughing up blood

If you experience any of these symptoms during or after treatment with HEMLIBRA, get medical help right away. 

Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total. 

Your body may make antibodies against HEMLIBRA, which may stop HEMLIBRA from working properly. Contact your healthcare provider immediately if you notice that HEMLIBRA has stopped working for you (eg, increase in bleeds).

The most common side effects of HEMLIBRA include: injection site reactions (redness, tenderness, warmth, or itching at the site of injection), headache, and joint pain. These are not all of the possible side effects of HEMLIBRA. You can speak with your healthcare provider for more information.

What else should I know about HEMLIBRA?

See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.

  • Stop taking your prophylactic bypassing therapy the day before you start HEMLIBRA
  • You may continue taking your prophylactic factor VIII for the first week of HEMLIBRA

HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and create an inaccurate result. Speak with your healthcare provider about how this may affect your care. 

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Only use HEMLIBRA for the condition it was prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist.

Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.

Since HEMLIBRA was tested in males, there is no information on whether HEMLIBRA may impact your unborn baby or breast milk. Females who are able to become pregnant should use birth control during treatment.

Side effects may be reported to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see Important Safety Information, including Serious Side Effects, as well as the HEMLIBRA full Prescribing Information and Medication Guide.